Discover how Siah2, an E3 ubiquitin ligase, drives castration-resistant prostate cancer and serves as a promising therapeutic target.
How nanoniosomes enhance ginsenoside Rh2 delivery for targeted prostate cancer therapy with improved efficacy and reduced side effects.